about
Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.An update on the use of ambrisentan in pulmonary arterial hypertension.Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia.Management von Patienten mit pulmonaler Hypertonie
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetic evaluation of ambrisentan.
@en
Pharmacokinetic evaluation of ambrisentan.
@nl
type
label
Pharmacokinetic evaluation of ambrisentan.
@en
Pharmacokinetic evaluation of ambrisentan.
@nl
prefLabel
Pharmacokinetic evaluation of ambrisentan.
@en
Pharmacokinetic evaluation of ambrisentan.
@nl
P2093
P2860
P1476
Pharmacokinetic evaluation of ambrisentan.
@en
P2093
Andrew S Varker
Anna K Kirejczyk
Jamie J Gibson
Jeremy P Feldman
Laura M Wicks
Mitchell S Buckley
Robin L Staib
P2860
P304
P356
10.1517/17425255.2011.557181
P407
P577
2011-02-08T00:00:00Z